房间隔缺损介入治疗现状与未来

www.yongyao.net　　2009-11-10 16:00:35　　来源：　　责任编辑：

分享到：

[ 参考文献]
[ 1 ] 　King TD,Mills NL. Secundum atrial sep tal defects: nonoperative closure during cardiac catheterization[ J ]. JAMA, 1976, 235: 2506-2509.
[ 2 ] 　RashkindWJ. Transcatheter treatment of congenital heart disease [ J ]. Circulation, 1993, 67: 711-716.
[ 3 ] 　Lock JE, Rome JJ ,Davis R, et al. Transcatheter closure of atrial sep tal defect: experiment study[ J ]. Circulation, 1989, 79: 1091-1099.
[ 4 ] 　Justo RN,Nykanen DG, Boutin C, et al. Clinical impact of transcatheter closure of secundum atrial sep tal defectswith the double umbrella device[ J ]. Am J Cardiol, 1996, 77: 889-892.
[ 5 ] 　Kaulita R, Paul T, Hausdorf G. Extending the limits of transcatheter closure of atrial defectswith the double umbrella device (CardioSEAL ) [ J ]. Heart, 1998,80: 54-59.
[ 6 ] 　AlanWN,Amy B, Kimb G, et al. Device closure rates of simp le atrial sep tal defects op timized by the STARFlex device [ J ]. J Am Coll Cardiol, 2006, 48: 538-544.
[ 7 ] 　Masura J , Gavora P, Formanek A, et al. Transcatheter closure of secundum atrialsep tal defects using the new self2centering Amp latzer sep tal occluder: initial human experience[ J ]. Cathet Cardiovasc Diagn, 1997, 42: 388-393.
[ 8 ] 　Latson LA, Zahn EM,W ilson N. Helex sep tal occluder for closure of atrial sep taldefects[ J ]. Curr Interv Cardiol Rep, 2000, 2: 268-273.
[ 9 ] 　Zahn EM,Wilson N, CutrightW, et al. Development and testing of the Helexsep tal occluder, a new expanded polytetrafluoroehylene atrial defect occlusionsystem [ J ]. Circulation, 2001, 104: 711-716.
[ 10 ] 　Thomas KJ , Larry AL, Zahn E, et al. Results of the U. S. multicenter p ivotal study of the Helex sep tal occluder for percutaneous closure of secundum atrialsep tal defects[ J ]. J Am Coll Cardiol, 2007, 49: 2215-2221.
[ 11 ] 　Jux C,Bertram H,Wohlsein P, et al. Interventional atrial sep tal defect closureusing a totally bioresoorbable occludermatrix: development and p reclinical evaluation of the B ioSTAR device[ J ]. J Am Coll Cardiol, 2006, 48: 161-169.
[ 12 ] 　Michael J , Daviad HS, Joseph V, et al. B ioSTAR evaluation study (BEST) , ap rospective,multicenter, phase I clinical trial to evaluation the feasibility, efficacy, and safety of the B ioSTAR bioabsorbable sep tal repair imp lant for the closure of atrial2level shunts[ J ]. Circulation, 2006, 114: 1962-1967.
[ 13 ] 　Steele P, FusterV, CohenM, et al. Isolated atrial sep tal defect with pulmonary vascular obstructive disease: long2term follow2up and p rediction of outcome after surgical correction[ J ]. Circulation, 1987, 76: 1037-1042.
[ 14 ] 　Jose S,AlfonsoM,Miguel R, et al. Effectiveness of percutaneous device occlusion for atrial sep tal defect in adult patients with pulmonary hypertension [ J ].Am Heart J , 2002, 144: 887-880.
[ 15 ] 　Schubert S, PetersB,Abdul2khaliq H, et al. Left ventricular conditioning in the elderly patient to p revent congestive heart failure after transcatheter closure of atrial sep tal defect[ J ]. Catheter Cardiovasc Interv, 2005, 61: 333-337.
[ 16 ] 　Holzer R, Cao QL, ZiyadM, et al. Closure of amoderately large atrial sep tal defectwith a self2fabricated fenestrated Amp latzer sep tal occluder in an 852yearold patientwith reduced diastolic elasticity of left ventricle [ J ]. Catheter Cardiovasc Interv, 2005, 64: 513-517.
[ 17 ] 　Marco P, Giuseppe S, Caso P, et al. Global and regional left ventricular function in patient undergoing transcatheter closure of secundum atrial sep tal defect[ J ].Am J Cardiol, 2005, 96: 439-442.
[ 18 ] 　Khairy P, O ’Donnell CP, LandzbergMJ. Transcatheter closure versus medical therapy of patent foramen ovale and p resumed paradoxical thromboemboli: asystematic review [ J ]. Ann InternMed, 2003, 139: 753-760.
[ 19 ] 　KrumsdorfU,Ostermayer S,B illinger K, et al. Incidence and clinical course of thrombus formation on atrial sep tal defect and patient foramen ovale closure devices in 1000 consecutive patients[ J ]. J Am Coll Cardiol, 2004, 43: 302-309.
[ 20 ] 　KnirschW,Dodge2KhatamiA,Balmer C, et al. Aortic sinus2left atrial fistula after interventional closure of atrial sep tal defect[ J ]. Catheter Cardiovasc Interv,2005, 66: 10-13.
[ 21 ] 　Amin Z, Hijazi ZM,Bass JL, et al. Erosion ofAmp latzer sep tal occluder device after closure of secundum atrial sep tal defects: review of registry of comp lications and recommendations to minimize future risk[ J ]. Catheter Cardiovasc Interv, 2004, 63: 496-502.
[ 22 ] 　Suda K, RaboissonMJ , Piette E, et al. Reversible atrioventricular block associated with closure of atrial sep tal defects using the Amp latzer device [ J ]. J AmColl Cardiol, 2004, 43: 1677-1682.
[ 23 ] 　Schwerzmann M, Nedeltchev K,Meier B. Patent foramen ovale closure: a new therapy formigraine[ J ]. Catheter Cardiovasc Interv, 2007, 69: 277-284.
[ 24 ] 　Josep RC, SophieM,AlierM, et al. Incidence, timing, and p redictive factors of new2onset migraine headache attact after transscatheter closure of atrial sep taldefect or patent foramen ovale[ J ]. Am J Cardiol, 2008, 101: 688-692.
[ 25 ] 　Kedhi E, Vermeersch TP. The influence of the percutaneous closure of atrialsep tal defect on the occurrence of migraine [ J ]. Eur Heart J , 2005, 26: 2746-2747.
[ 26 ] 　RiesMW, Kampmann C, Rupp recht HJ , et al. Nickel release after imp lantation of the Amp latzer occluder[ J ]. Am Heart J , 2003, 145: 737-741.
[ 27 ] 　Wertman B,AzarbalB, RiedlM, et al. Adverse events associated with nickel allergy in patients undergoing percutaneous atrial sep tal defect or patent foramenovale closure[ J ]. J Am Coll Cardiol, 2006, 47: 1226-1227.